CG Oncology

Company snapshot

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgonco

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 US patent(s) indexed to this assignee profile.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for CG Oncology. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for CG Oncology.

1. May 23, 2026 Clinical update

   CG0070 Adenovirus Vector — Phase 3

2. May 23, 2026 Clinical update

   Cretostimogene Grenadenorepvec — Phase 3

3. May 23, 2026 Clinical update

   CG0070 — Phase 2

4. May 23, 2026 Clinical update

   CG0070 — Phase 2

5. May 23, 2026 Clinical update

   Cretostimogene Grenadenorepvec — Phase 2

View all clinical trial activity →

• What is CG Oncology?

  CG Oncology is a biotech organization headquartered in Dallas, USA. It trades on NYSE under ticker CGON. Primary therapeutic focus areas include Bladder Cancer, Non Muscle Invasive Bladder Cancer, Transitional Cell Carcinoma, Muscle-Invasive Bladder Carcinoma, High-Risk Non-Muscl

• Is CG Oncology publicly traded?

  Yes. CG Oncology is listed with ticker CGON on NYSE per SEC EDGAR records linked on this profile.

• What drugs does CG Oncology develop or market?

  We link 1 drug profile(s) where CG Oncology is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cg-oncology#company-drugs.

• What are the latest developments for CG Oncology?

  In the last 12 months our linked public records show 8 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does CG Oncology focus on?

  CG Oncology focuses on Bladder Cancer, Non Muscle Invasive Bladder Cancer, Transitional Cell Carcinoma based on our analysis of their pipeline programs and drug development activities.